Company: PRME
Filing Date: 2025-07-02
Form Type: PRE 14A
Source: 0001193125-25-155000
Chunk: 11

Company: Prime Medicine, Inc.
Filing Date: 2025-07-02
Form: PRE 14A
Chunk 11
---
Our Board is
making this solicitation of proxies for our Special Meeting. We will bear all costs of such solicitation, including the cost of preparing and distributing this proxy statement and the enclosed form of proxy card and including the cost of hosting the
virtual Special Meeting. After the initial distribution of this proxy statement, proxies may be solicited by mail, telephone or personally by directors, officers, employees or agents of the Company. Brokerage houses and other custodians, nominees
and fiduciaries will be requested to forward soliciting materials to beneficial owners of shares held by them for the accounts of beneficial owners, and we will pay their reasonable
out-of-pocket expenses.

Special Meeting Voting Results

We plan to announce preliminary voting results at the Special Meeting and will publish final results in a Current Report on Form 8-K (a “Form 8-K”) to be filed with the SEC within four (4) business days following the Special Meeting. If final voting results are not available to us in time
to file a Form 8-K within four (4) business days after the Special Meeting, we intend to file a Form 8-K to publish preliminary results and, within four
(4) business days after the final results are known to us, file an amendment to the Form 8-K to publish the final results.

7

PROPOSAL 1— APPROVAL OF REPRICING OF CERTAIN OUTSTANDING STOCK OPTIONS

Overview

We are
seeking stockholder approval of a proposed one-time repricing (the “Option Repricing”) of certain outstanding stock options granted to, and held by, certain of our current employees, including our
executive officers, and members of the Board through the Repricing Date (as defined below) (collectively, the “Eligible Optionholders”), under our 2019 Stock Option and Grant Plan (as may be amended, restated or otherwise modified from
time to time in accordance with its terms, the “2019 Plan”) and 2022 Stock Option and Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the “2022 Plan” and, together
with the 2019 Plan, the “Plans”), that have exercise prices in excess of the Repriced Exercise Price (as defined below), covering up to an aggregate of 8,285,387 shares of our common stock (such options, the “Eligible Options”).
The Eligible Options